TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02735096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EquiCue (Intraoral Electronic Balance Aid)
Description: When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
Study: NCT02371564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow humidified oxygen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard flow humidified oxygen
Study: NCT03979183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbopelvic, stretching, aerobic and relaxation exercises
Description: Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
Study: NCT03250585

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhaled Breath Condensate (EBC)
Description: Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Sample
Description: Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
Study: NCT04959214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation egzersize
Description: Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
Study: NCT01636947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant Placebo
Description: Aprepitant Placebo (PO, QD) on Days 1, 2, and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (20 mg or 12 mg, PO) on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg or 12 mg, PO) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron Placebo (PO, BID) on Days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Description: Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
Study: NCT02706171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study: NCT03968055

Intervention type: OTHER
Group type: OTHER
Intervention: Integration with Epic
Description: Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
Study: NCT04312594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Patients were administered Jaktinib taken orally as tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Patients were administered Jaktinib taken orally as tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were administered Placebo taken orally as tablets twice daily
Study: NCT02007044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04524585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade
Description: Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
Study: NCT03881059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986165 Placebo
Description: Participants will receive BMS-986165 matching placebo QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose A
Description: Participants will receive BMS-986165 Dose A QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose A
Description: Participants will receive BMS-986165 Dose A QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose B
Description: Participants will receive BMS-986165 dose B QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Dose B
Description: Participants will receive BMS-986165 dose B QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive ustekinumab SQ injection QD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ustekinumab Placebo
Description: Participants will receive ustekinumab SQ matching placebo QD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ustekinumab Placebo
Description: Participants will receive ustekinumab SQ matching placebo QD
Study: NCT02204293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canakinumab
Description: Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered subcutaneously.
Study: NCT01932138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced CHW intervention
Description: The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
Study: NCT00827151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen
Description: Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
Study: NCT02293837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
Study: NCT01757067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC ablation
Description: This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
Study: NCT01223222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LTX-109
Description: Topical administration. 3 times daily. 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109
Description: Topical administration. 3 times daily. 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109
Description: Topical administration. 3 times daily. 5 days.
Study: NCT00849680

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
Description: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine
Description: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
Description: Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
Description: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
Description: Placebo to the MRKAd5 HIV-1 gag vaccine.
Study: NCT00786474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution, dosage determined by weight, self-administered by patient twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
Study: NCT02926508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bimuno (BGOS)
Description: The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
Study: NCT03411889

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scanning
Description: MRI scanning during tear drainage
Study: NCT02663375

Intervention type: DEVICE
Intervention: ACURATE TA™ Transapical Aortic Bioprosthesis
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
Study: NCT02631811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive /palliative care intervention
Description: patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
Study: NCT02532322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
Study: NCT01534455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib + 1,23 mg Eribulin
Description: Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib + 1,76 mg Eribulin
Description: Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
Study: NCT02521324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DGB2
Description: DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DGB2
Description: DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
Study: NCT02685371

Intervention type: BEHAVIORAL
Intervention: Breathing
Description: Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
Study: NCT03759366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered by IV infusion.
Study: NCT03441282

Intervention type: DRUG
Intervention: Fentanyl
Description: After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia.
Study: NCT01561456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Study: NCT04497350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
Study: NCT01523704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTRONIK Home Monitoring System
Description: Home Monitoring system transfers implantable device's data to the main server via internet.
Study: NCT01561456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Study: NCT02251340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eczema Care Plan
Study: NCT04529811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin Novel Formulation
Description: Rifaximin Novel Formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02702336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EYTO-kids
Description: To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
Study: NCT03243500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: 5mg in 1 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronidase powder
Description: 1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: hyaluronidase powder
Description: 1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: per-caruncular peribulbar injection
Description: The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
Study: NCT01523704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTRONIK Home Monitoring System with In-office Follow-up
Study: NCT04312282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel orally on Day 1 of a 21-day cycle